Actively Recruiting
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
Led by National Cancer Institute, Naples · Updated on 2025-12-22
300
Participants Needed
2
Research Sites
287 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is multicentric, spontaneous, observational, retrospective and prospective study.
CONDITIONS
Official Title
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- TNBC breast cancer patients, before any drug treatment
- Healthy women aged 25-60
You will not qualify if you...
- Donors with diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease, or drug treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Istituto Nazionale Tumori - Fondazione "G.Pascale", IRCCS
Naples, Napoli, Italy, 80131
Actively Recruiting
2
Istituto Nazionale Tumori Regina Elena
Roma, Roma, Italy, 00144
Actively Recruiting
Research Team
E
Elena Di Gennaro, PhD
CONTACT
S
Susan Costantini, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here